These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 26806184)

  • 1. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
    Pelletier JP; Martel-Pelletier J; Rannou F; Cooper C
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S22-7. PubMed ID: 26806184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting.
    Bruyère O; Cooper C; Pelletier JP; Maheu E; Rannou F; Branco J; Luisa Brandi M; Kanis JA; Altman RD; Hochberg MC; Martel-Pelletier J; Reginster JY
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S3-11. PubMed ID: 26806188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
    Rannou F; Pelletier JP; Martel-Pelletier J
    Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S18-21. PubMed ID: 26806189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.
    Jones P; Lamdin R
    Clin Drug Investig; 2010; 30(7):419-37. PubMed ID: 20527999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
    Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
    Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
    BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.
    Scarpignato C; Lanas A; Blandizzi C; Lems WF; Hermann M; Hunt RH;
    BMC Med; 2015 Mar; 13():55. PubMed ID: 25857826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.
    Lanas A; Garcia-Tell G; Armada B; Oteo-Alvaro A
    BMC Med; 2011 Apr; 9():38. PubMed ID: 21489310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
    Lanas A; Tornero J; Zamorano JL
    Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis.
    Silverman S; Schepman P; Rice JB; Robinson RL; White AG; Fernan C; Beck CG
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1652-1660. PubMed ID: 34818088
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical review of chondroitin sulfate in osteoarthritis.
    Uebelhart D
    Osteoarthritis Cartilage; 2008; 16 Suppl 3():S19-21. PubMed ID: 18674931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
    Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.